The pseudo vaccine method is used to help with the stages of testing during development and study of vaccines for disease screening.
Certain social media posts and videos claim that pseudo vaccines were created to manipulate psychological terror among people. Many of these posts cite doctors and medical institutes; however, this is false and a conspiracy theory.
According to the National Library of Medicine, Pseudo typed viruses are a validated and viable tool for researching numerous aspects of virus biology in a low-containment biosafety facility. A pseudo vaccine method is used to help in the development and research of vaccines for disease screening. However, it is not intended for use by the general public.
The Ebola crisis timely conference examined recent advances in pseudo-type technology and how they are revolutionizing the study of important human and animal pathogens such as human and avian influenza viruses, rabies, HIV, Marburg, and Ebola viruses.
According to ScienceDirect, a pseudo viral system is used to test vaccine efficacy or immunogenicity in emerging and re-emerging viruses. Using pseudo-virus systems instead of real highly pathogenic viruses in a high-biosafety laboratory might speed up the vaccine development process and give population protection against new and re-emerging viral illnesses with high pathogenicity. The pseudo-virus system, which is handled in a level 2 biosafety facility, has been frequently used to test vaccination effectiveness and antigenic analysis.
According to the World Health Organization (WHO), the pseudo vaccine method is used to help develop and study the vaccine for effectively screening vaccinations against disease trials at different stages of development. Phase 1 trials evaluate safety and immunogenicity in a small population of healthy human volunteers, often studying different doses and vaccination schedules. Phase 2 will expand to a broader and more targeted population to gather safety and immunogenicity data for a more extensive following efficacy research. Phase 3 will culminate in a randomized clinical trial quantifying preventive vaccine protection against the disease.